Immunophenotypic characterization of normal blood CD56+lo versus CD56+hi NK‐cell subsets and its impact on the understanding of their tissue distribution and functional properties by LIMA, M. et al.
gs
f
C
C
t
I
P
I
Lima et al. Blood Cells, Molecules, and Diseases (2001) 27(4) July/Aug: 731–743
doi:10.1006/bcmd.2001.0443, available online at http://www.idealibrary.com onImmunophenotypic Characterization of Normal Blood CD561lo
Versus CD561hi NK-Cell Subsets and Its Impact
on the Understanding of Their Tissue Distribution
and Functional Properties
Submitted 07/12/01
(Communicated by M. Lichtman, M.D., 07/12/01)
Margarida Lima,1,2 Maria dos Anjos Teixeira,1 Maria Luı´s Queiro´s,1 Marina Leite,1
Ana Helena Santos,1 Benvindo Justic¸a,1 and Alberto Orfa˜o3
ABSTRACT: In the present study we have compared the immunophenotypic characteristics of the CD561lo and
CD561hi NK-cell subsets in a group of normal healthy adults. Our results show that CD561hi NK-cells display
reater light-scatter properties than CD561lo NK-cells at the same time they have higher levels of CD25 and
CD122 IL-2 chains, together with a higher reactivity for HLA-DR and CD45RO and lower levels of CD45RA,
supporting that, as opposed to the majority of the CD561lo population, CD561hi NK-cells might correspond to a
ubset of activated circulating NK-lymphocytes. Higher expression of the CD2 and CD7 costimulatory molecules
ound for the CD561hi NK-cells would support their greater ability to respond to various stimuli. In addition,
D561hi NK-cells expressed higher levels of several adhesion molecules such as CD2, CD11c, CD44, CD56, and
D62L compared to CD561lo NK-cells, supporting a particular ability of these cells to migrate from blood to
issues and/or a potential advantage to form conjugates with target cells. Interestingly, CD561lo and CD561hi
NK-cells showed a different pattern of expression of killer receptors that might determine different activation
requirements for each of these NK-cell subsets. For instance, absence or low levels of CD16 expression might
explain the lower antibody-dependent cytotoxicity activity of CD561hi NK-cells. On the other hand, the virtual
absence of expression of the CD158a and NKB1 immunoglobulin-like and the greater reactivity for the CD94
lectin-like killer receptors on CD561hi in comparison to CD561lo NK-cells might determine different MHC-class
specificities for both NK-cell subsets, a possibility that deserves further studies to be confirmed. © 2001 Academic
ressKey Words: NK-cells; immunophenotype; flow cytometry; CD56; blood.
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Natural killer (NK) cells are commonly de-
fined as CD32/TCR2 large granular lymphocytes
that express CD56 and/or CD16 and mediate non-
MHC restricted cytotoxic functions (1). Two ma-
jor NK-cell subsets differing on the expression of
CD56 on the cell surface have been described so
far: CD561lo and CD561hi NK cells (2). CD561lo
NK-cells predominate in blood whereas CD561hi
NK-cells are more frequently detected in various
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2 Correspondence and reprint requests to: Margarida Lima, Servic¸o de Hem
I, s/n, 4050 Porto, Portugal. Fax: 351-22-6004808. E-mail: mmc.lima@clix.pt.
3 Servicio de Citometrı´a, Universidad de Salamanca and Centro de Investigacio´n
731organs and tissues including the uterine placenta
decidua (3–5), as well as in the lymphatic fluid
(5). Although it was initially suggested that
CD561hi could represent precursors of the most
numerous CD561lo NK-cells (6), it was recently
shown that CD561hi NK-cells represent a func-
ionally distinct subset of mature NK-cells which
re primarily responsible for cytokine production
n response to monokines (7). In spite of this, it
till remains unclear whether CD561lo and
nto´nio, Porto, Portugal.
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f NK-cells or alternatively they represent differ-
nt maturational/activation states of the same NK-
ell population. Preliminary studies indicated that
D561lo and CD561hi NK-cells show different
atterns of expression several surface markers (6,
), suggesting that a detailed characterization of
he molecules expressed on these NK-cell subsets
ould potentially contribute to clarify the relation-
hip between them; nevertheless, at present infor-
ation on the immunophenotypic features of both
K-cell subsets is not detailed enough to provide
comprehensive view of their tissue distribution
nd functional properties.
To gain further insights into the relationship
etween these subsets of blood NK-cells in the
resent study we have compared the immunophe-
otypic characteristics of CD561hi with those of
the predominating CD561lo NK-cells, as regard to
the expression of killer receptors, activation-re-
lated markers, cell adhesion molecules and hom-
ing receptors; based on the differences observed,
we discuss on the functional relevance of each of
these groups of molecules in determining NK-cell
function and migratory properties.
MATERIALS AND METHODS
Samples
The enumeration of CD561lo and CD561hi
NK-cells and the immunophenotypic analysis of
these NK-cell subsets were performed in fresh
EDTA-K3 anti-coagulated blood samples from
six healthy adult individuals (blood donors)—
three males and three females—aged from 24 to
38 years (median age of 32 years) who gave
informed consent to enter in this study.
Immunophenotypic Studies
Immunophenotypic studies were performed
using a whole blood stain-lyse-and-then-wash
method and a direct immunofluorescence tech-
nique. Briefly, 100 ml of whole blood containing
between 0.5 and 2 3 106 nucleated cells was
incubated for 15 min at room temperature (RT) in
the darkness, with saturating amounts of the ap-
732propriate monoclonal antibodies (MoAb). Lysis
of red blood cells and fixation of the leukocytes
was then performed by adding 2 ml of FACS
lysing solution [Becton/Dickinson Biosciences
(BD), San Jose, CA) diluted 1/10 (v/v) in distilled
water and incubating the cells for another 10 min
at RT. Cells were then washed once by centrifug-
ing at 540g and resuspended in 0.5 ml of phos-
phate-buffered saline (PBS) for acquisition in the
flow cytometer.
The following four-color combinations of
MoAb directed against T- and NK-associated
antigens conjugated with fluorescein isothio-
cyanate (FITC)/phycoerythrin (PE)/PE-Cyanine
5 (PE-Cy5) and/allophycocyanin (APC) were
used: CD2/CD7/CD56/CD3, CD5/CD7/CD56/
CD3, CD57/CD11c/CD56/CD3, CD38/CD11b/
CD56/CD3, CD16/NKB1/CD56/CD3, CD158a/
CD161/CD56/CD3, CD94/CD8/CD56/CD3, CD122/
CD25/CD56/CD3, CD44/CD40L/CD56/CD3,
CD11a/HLA-DR/CD56/CD3, CD45RA/CD45RO/
CD56/CD3, and CD62L/CD28/CD56/CD3. The
source and specificity of each of the MoAb reagents
are shown in Table 1.
Data acquisition was carried out in a FACS-
Calibur flow cytometer (BD) equipped with a
15-mW air-cooled 488-nm argon laser and a
625-nm neon diode laser, using the Cell QUEST
software program (BD). Information on a mini-
mum of 2 3 105 events was acquired for each
staining and stored as list mode data. For data
analysis the Paint-a-Gate PRO software program
(BD) was used. As a first step, NK-cells were
selected based on their CD32/CD561 phenotype
and the proportion of CD561lo and CD561hi NK-
ells within the total CD561 NK-cell compart-
ment calculated. Then, each NK-cell subset was
separately analyzed for both its light-scatter—side
scatter (SSC) and forward scatter (FSC)—char-
acteristics and expression of the surface antigens
recognized by the MoAb referred above. For each
antigenic determinant, the following characteris-
tics were recorded: (i) percentage of positive cells,
evaluated as the percentage of cells stained above
the negative control value; (ii) intensity of expres-
sion, evaluated by the mean fluorescence intensity
(MFI), expressed in arbitrary relative linear units
of fluorescence scaled from 0 to 10,000; (iii)
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sus heterogeneous—evaluated by the coefficient
of variation (CV). In addition, the relative inten-
sity of expression of each antigen on CD561hi
NK-cells compared to CD561lo NK-cells was
valuated as the ratio between the MFI values for
hese NK-cell subsets in each individual sample.
tatistical Analysis
For all variables under study, median, mean,
tandard deviation, minimum and maximum were
alculated. To establish the statistical significance
f the immunophenotypic differences observed
etween CD561lo and CD561hi NK-cells, the
Mann–Whitney U and the x2 tests were used, for
ontinuous and dichotomic variables (SPSS 9.0,
TABLE 1
Specificities, Clones, and Sources of the Monoclonal Antibodies
Used in the Present Study
Specificity Clone Conjugate Sourcea
CD2 SFCI3Pt2H9 FITC BC
CD3 SK7 APC BD
CD5 L17F12 PE BD
CD7 3A1/1,7F3; 3A1E-12H7 FITC; PE CLB; BC
CD8 DK25 PE DK
CD11a CLB-LFA-1/2 FITC CLB
CD11b D12 PE BD
CD11c S-HCL-3 PE BD
CD16 3G8 FITC BC
CD25 2A3 PE BD
CD28 L293 PE BD
CD38 LD38 FITC CYT
CD44 L178 FITC BD
CD45RA L48 FITC BD
CD45RO UCHL-1 PE BD
CD56 NCAM16.2 PE BD
CD57 HNK-1 FITC BD
CD62L SK11 FITC BD
CD94 HP-309 FITC PH
CD122 MIK-b FITC CLB
CD154 TRAP1 PE PH
CD158a HP-3E4 FITC BD
CD161 DX12 PE BD
HLA-DR L243 PE BD
NKB1 DX9 PE BD
a BC, Beckman Coulter (Miami, FL); BD, Becton/Dickinson
ioSciences (San Jose´, CA); CLB (Amsterdam, The Netherlands);
YT, Cytognos (Salamanca, Spain); DK, Dako A/S (Gostrup,
enmark); PH, Pharmingen (San Diego, CA).PSS, Chicago, IL). P values less than 0.05 were
733onsidered to be associated with statistically sig-
ificant differences.
ESULTS
CD561 NK-cells accounted for a mean of
7 6 8% of the blood lymphocyte compartment
n the blood from the 6 normal individuals in-
luded in this study, the mean absolute NK-cell
ount being of 264 6 183 3 106/L. From the
K-cells, the majority showed dim CD56 expres-
ion (CD561lo) (mean of 93 6 7%, ranging from
0 to 99%) while a minor fraction displayed a
igh reactivity for CD56 (CD561hi) (7 6 7%,
ranging from 1 to 20%). These values did not
differ significantly from those found in a group of
70 healthy adult individuals used for determina-
tion of normal reference values in our lab (93 6
6% versus 7 6 6%).
Apart from their differential expression of
D56 these NK-cell subsets displayed distinct
ight-scatter (FSC and SSC) characteristics. Ac-
ordingly, CD561hi NK-cells showed higher FSC
P 5 0.041) and SSC (P 5 0.026) values
han those observed for CD561lo NK-cells, with
dentical FSC and SSC mean ratios (1.1 6 0.1).
From the phenotypic point of view, CD561hi
NK-cells expressed CD56 at levels that were 6.7-
6 1.5-fold higher than those observed for
CD561lo NK-cells (P 5 0.002) (Fig. 1), which
n turn exceeded those of CD561 T-cells by 3.3-
6 1.5-fold. Interestingly, CD56 expression was
extremely homogeneous on CD561hi compared to
the CD561lo NK-cells (P 5 0.002).
Besides the differential expression observed
for CD56, the two NK-cell populations under
study also differed in the percentage of cells that
stained positively (Table 2) and/or on the intensity
and pattern of expression (Table 3 and Fig. 1) of
a large number of other antigens. Such phenotypic
differences are illustrated in Fig. 2 and described
below in more detail.
T-Cell-Associated Markers
None of the two blood NK-cell subsets showed
surface expression of CD3. By contrast, both NK-
cell subsets expressed the CD2 and CD7 antigens,
s
t
c
f
C
N
r
A
h
p
s
C
i
w
s
d
c
C
s
m
Blood Cells, Molecules, and Diseases (2001) 27(4) July/Aug: 731–743 Lima et al.
doi:10.1006/bcmd.2001.0443, available online at http://www.idealibrary.com onalthough in both cases a CD22 NK-cell population
was identified which represented a mean of 23 6 11
and 6 6 3% of CD561lo and CD561hi NK-cell
ubsets, respectively (P 5 0.004). Upon comparing
he reactivity for both antigens in the CD561hi and
CD561lo NK-cell subsets it was observed that the
former expressed CD2 and CD7 at higher intensities
than those observed on CD561lo cells (ratio of
2.6 6 0.6 and 2.9 6 1.2, respectively; P 5 0.002
in both cases). In addition, both CD2 and CD7 were
more heterogeneously expressed on CD561low than
on CD561hi NK-cells (P 5 0.004 and 0.041, re-
spectively). A variable proportion of CD561lo NK-
ells showed dim CD5 expression (5 6 7%, ranging
rom 0 to 18%), a CD561lo/CD51lo NK-cell popu-
lation being clearly identified in 3 out of 6 cases,
where they represent 2, 9, and 18% of total CD561lo
NK-cells; in these cases, CD5 expression was ho-
mogeneous, and present at levels 9.6- 6 1.2-fold
lower than those observed for normal blood T-cells.
In contrast, CD561hi NK-cells were consistently
negative for CD5 (P 5 0.001).
The mean fraction of CD81 cells within the
D561lo (55 6 16%) and the CD561hi (54 6 13%)
K-cell subsets were similar, CD8 expression being
FIG. 1. Ratio between the intensity of antigen expre
ubsets from six adult healthy individuals. Horizontal lines re
aximum values.ather heterogeneous in both cases.
734dhesion Molecules and Homing Receptors
Virtually all NK-cells constitutively expressed
omogeneously high levels of CD11a when com-
ared to other circulating lymphocytes, its inten-
ity of expression being significantly lower on
D561hi NK-cells compared to the predominat-
ng CD561lo NK-cell subset (ratio of 1.4 6 0.2;
P 5 0.002). In contrast, CD11b was heteroge-
neously expressed on both cell subsets at similar
levels (P . 0.05) whereas CD11c expression
as significantly higher on the latter NK-cell sub-
et (ratio of 1.6- 6 0.3-fold; P 5 0.041). Ad-
itionally, most CD561hi NK-cells were CD11c1
(92 6 6%) whereas its expression on CD561lo
NK cells was more variable, with a mean fraction
of 72 6 24% CD11c1 cells (P 5 0.065).
Expression of CD11c was relatively heteroge-
neous on both NK-cell subsets, although lower
coefficients of variation were found on CD561hi
than on CD561lo NK-cells (P 5 0.009). In
ontrast, CD57 was expressed in large fraction of
D561lo NK whereas CD561hi were virtually
negative for CD57 (mean fraction of CD571 cells
of 66 6 14 and 1 6 1%, respectively; P 5
(MFI) obtained on CD561hi and CD561lo blood NK-cell
nt median values and vertical lines extend the minimum andssion
prese0.002).
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being significantly higher (ratio of 4.1 6 1.1;
P 5 0.002) and more homogeneous (P 5
0.032) on CD561hi compared to CD561lo NK-
cells. In addition, nearly all CD561lo NK-cells
expressed CD62L whereas this molecule was neg-
ative or dimly positive in only a minor fraction of
CD561lo NK-cells (100 6 0% versus 14 6 7%;
P 5 0.002).
iller Receptors
In contrast to the CD561lo NK-cell compart-
ent, in which the majority of cells (98 6 16%)
omogeneously expressed CD16, CD561hi NK-
TABLE 2
Immunophenotypic Characteristics of CD561lo and CD561hi
Peripheral Blood NK-Cell Subsets from Adult Healthy
Individuals (n 5 6)
CD561 NK-cells
P valueCD561lo CD561hi
CD2 77 6 11 (64–91) 94 6 3 (91–98) 0.004
CD5a 5 6 7 (0–18) 0 6 1 (0–1) 0.180
D7 99 6 1 (98–100) 94 6 5 (85–99) 0.015
D8 55 6 16 (40–72) 54 6 13 (41–66) 1.000
D11a 100 6 0 (99–100) 100 6 0 (100–100) 1.000
D11b 92 6 13 (68–100) 84 6 8 (71–90) 0.151
D11c 72 6 24 (28–93) 92 6 6 (84–100) 0.065
D16 98 6 2 (95–100) 28 6 16 (10–47) 0.009
D25 1 6 1 (0–2) 22 6 9 (9–32) 0.002
D38 99 6 2 (95–100) 99 6 2 (97–100) 0.584
D44 100 6 1 (97–100) 100 6 2 (94–100) 1.000
D45RA 100 6 0 (100–100) 98 6 2 (96–100) 1.000
D45RO 4 6 4 (1–12) 12 6 5 (9–17) 0.026
D57 66 6 14 (52–91) 1 6 1 (0–2) 0.002
D62L 14 6 7 (4–22) 100 6 0 (99–100) 0.002
D94 59 6 11 (40–75) 98 6 3 (90–100) 0.000
D122 100 6 0 (100–100) 100 6 0 (100–100) 0.937
D158a 18 6 8 (10–25) 1 6 0 (0–1) 0.037
D161 83 6 11 (63–95) 59 6 25 (31–96) 0.132
LA-DR 23 6 13 (10–46) 83 6 8 (74–92) 0.002
KB1 16 6 16 (0–47) 0 6 1 (0–1) 0.026
Note. Results are expressed as means 6 standard deviation of
ercentage of positive cells; range is shown in parentheses. CD3,
D28, and CD40L were constantly absent in NK-cells from the
amples analyzed.
a A CD561lo/CD51lo NK-cell population was clearly identified
n three of six cases, where they represent 2, 9, and 18% of total
D561lo NK-cells, while CD561hi were constantly CD52 (x2 test,
P 5 0.001).ells either lacked CD16 or showed CD16 expres-
735ion in a relatively small fraction of cells (mean of
8 6 16%; P 5 0.009) at an intensity 5.5- 6
.3-fold lower than that observed for the CD561lo
NK-cell population (P 5 0.009).
The expression of the immunoglobulin-like
KB1 and CD158a killer receptors on CD561lo
NK-cells was highly variable (mean percentage of
positive cells of 16 6 16 and 18 6 8%, ranging
rom 0 to 47% and from 10 to 25%, respectively)
hereas both were constantly negative on
D561hi NK-cells (P 5 0.026 and 0.037, re-
spectively).
In that concerning lectin-like killer receptors,
virtually all CD561hi NK-cells expressed CD94
whereas only around half (59 6 11%) of CD561lo
NK-cells showed dim CD94 expression, the in-
tensity of expression for this molecule being 2.6-
6 0.3-fold higher (P 5 0.007) and more ho-
mogeneous (P , 0.001) on CD561hi compared
o CD561lo NK-cells. In contrast, reactivity for
CD161 was relatively heterogeneous in both NK-
cell subsets, although the intensity of CD161 ex-
pression was higher on CD561hi NK-cells (P 5
.004).
ostimulatory Molecules, Cytokine Receptors,
nd Activation-Related Markers
All NK-cells constitutively expressed high
evels of CD45RA. The intensity of CD45RA
xpression was 1.7- 6 0.7-fold higher (P 5
.016) and more homogeneous (P 5 0.026) on
D561lo than on CD561hi NK cells. Although the
ast majority of NK-cells were CD45RO2, a few
D45RA1/CD45RO1 NK-cells were detected
ithin both cell subsets, its percentage being
igher among CD561hi NK-cells (12 6 5% ver-
sus 4 6 4%; P 5 0.026). In both cases
D45RO1/CD45RA1 NK-cells expressed lower
levels of CD45RA than CD45RA1CD45RO2
NK-cells, expression of CD45RO being con-
stantly dim and heterogeneous.
CD122 was constitutively expressed on virtu-
ally all NK-cells, its intensity of expression being
2.3- 6 0.6-fold higher on CD561hi NK-cells
P 5 0.002). Few CD561lo NK-cells coex-
pressed CD25 (1 6 1%) whereas a relatively high
proportion of CD561hi NK-cells was CD251lo
C
P
p
0
s
a
C
D
p
t
p
l
p
Blood Cells, Molecules, and Diseases (2001) 27(4) July/Aug: 731–743 Lima et al.
doi:10.1006/bcmd.2001.0443, available online at http://www.idealibrary.com on(22 6 9%) (P 5 0.002). The mean proportion
of HLA-DR1 cells was also higher among
D561hi NK-cells (83 6 8% versus 23 6 13%;
5 0.002). Both NK-cell populations dis-
layed similar patterns of CD38 expression (P .
.05).
The CD28 costimulatory molecule was con-
tantly absent in the two NK-cell subsets here
nalyzed in all blood samples studied, as did the
D40 ligand (CD154).
ISCUSSION
In the present study we confirm and extend
revious observations as regards the presence in
he blood from normal individuals of two distinct
opulations of NK-cells defined by differential
evels of CD56 expression. While the CD561lo
subset constantly represent the major fraction of
TA
Immunophenotypic Characteristics of CD561lo and CD561hi
(n 5 6): Intensity and Pattern o
MFI
CD561lo CD561hi
CD2 192 6 70 476 6 77
CD5 205 6 33 Negative
CD7 1585 6 314 4409 6 1300
CD8 423 6 176 230 6 66
CD11a 548 6 109 343 6 67
CD11b 91 6 37 61 6 18
CD11c 162 6 34 258 6 84
CD16 236 6 161 47 6 39
CD25 24 6 20 24 6 14
CD38 110 6 42 146 6 46
CD44 38 6 20 145 6 31
CD45RA 308 6 35 194 6 64
CD45RO 37 6 7 63 6 18
CD56 488 6 148 3071 6 461
CD57 698 6 303 Negative
CD62L 27 6 7 49 6 16
CD94 60 6 9 161 6 43
CD122 30 6 10 63 6 12
CD158a 27 6 17 Negative
CD161 48 6 18 23 6 7
HLA-DR 79 6 23 93 6 34
NKB1 225 6 72 Negative
Note. Results are expressed as means 6 standard deviation of th
of antigen expression on positive cells. MFI are expressed as arbitr
were constantly absent in NK-cells from the samples analyzed.NK-cells, the CD561hi only accounts for a minor
736roportion of CD561 NK-cells present in blood.
Interestingly, these NK-cell subsets showed dis-
tinct light scatter properties, higher FSC and SSC
values being found for the CD561hi NK-cells,
supporting the existence of differences between
these NK-cell subsets as regards both size and the
cell internal complexity/granularity. Additionally,
both cell subsets displayed distinct immunophe-
notypic patterns for a great part of the surface
proteins analyzed, which may be related to dis-
tinct functional and migratory properties (9–15).
As an example, receptors that regulate adhesion to
vascular endothelium and extracellular matrix
might contribute to a differential representation of
these NK-cell subsets in blood as well as in tis-
sues; in a similar way, differences on the expres-
sion of killer receptors, NK-cell costimulatory
molecules and cytokine receptors may have a
determinant role on the differential capacity of
3
eral Blood NK-Cell Subsets from Adult Healthy Individuals
ession of Each Antigen Analyzed
alue
CV
P valueCD561lo CD561hi
02 55 6 8 38 6 5 0.004
42 6 6 Negative —
02 81 6 21 54 6 15 0.041
00 115 6 13 127 6 6 0.400
02 32 6 2 31 6 3 0.240
22 103 6 11 107 6 18 0.541
41 97 6 12 72 6 10 0.009
09 45 6 12 65 6 22 0.132
89 129 6 42 107 6 20 1.000
21 88 6 23 79 6 8 0.730
02 83 6 22 48 6 13 0.032
16 34 6 7 57 6 16 0.026
16 154 6 80 114 6 12 0.699
02 53 6 7 35 6 6 0.002
110 6 27 Negative —
15 62 6 11 51 6 11 0.132
07 65 6 5 38 6 3 0.000
02 62 6 12 44 6 12 0.093
67 6 8 Negative —
04 65 6 6 73 6 6 0.056
89 153 6 63 127 6 14 0.485
46 6 9 Negative —
fluorescence intensity (MFI) and the coefficient of variation (CV)
tive linear units scaled from 0 to 10,000. CD3, CD28, and CD40LBLE
Periph
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P v
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doi:10.1006/bcmd.2001.0443, available online at http://www.idealibrary.com onFIG. 2. Representative dot plots illustrating the distinct immunophenotypic patterns observed for the CD561lo (red dots)
and CD561hi (black dots) blood NK-cells subsets from an adult healthy individual. Events painted in gray correspond to blood
T-cells present in the sample.
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that trigger and regulate cytotoxic functions.
In that concerning to adhesion molecules that
may favor homing of NK-cells to different tis-
sues, it should be noted that CD62L—the L-se-
lectin adhesion molecule that mediates interaction
of leukocytes with peripheral lymph node high
endothelial venules (HEV) (16, 17)—and
CD44—a molecule that mediates adhesion by
acting as the hyaluronate receptor and promotes
NK-cell homing by binding to mucosal HEV (18,
19)—were preferentially expressed in CD561hi
compared CD561lo NK-cells in accordance to
previous observations (8, 20). These findings
might at least in part explain why CD561hi more
fficiently bind to HEV than CD561lo NK-cells
20) and could contribute to a preferential homing
f CD561hi NK-cells into different human tissues
where they are found at higher frequencies (3–5).
Other adhesion molecules, such as the b1-
ntegrins (21) have also been shown to be in-
olved in the adhesion to vascular endothelium
nd transmigration across endothelial cells by
eans of different interactions, including those
etween CD11a and CD11b and their ligands
CD54, CD102, and fibrinogen) (22–30). In the
resent study we show, in accordance to previous
tudies (8), that CD11a is expressed on NK-cells
t higher levels than those observed in other blood
ells, a characteristic that probably contributes to
he greater migratory properties of NK-cells com-
ared to other circulating lymphocyte subsets.
evertheless, differences on the expression of
D11a cannot explain the preferential localiza-
ion of CD561hi compared to CD561lo NK-cells
n tissues, as the intensity expression of CD11a is
lightly lower in the former NK-cell subset. For
he same reasons, differences on the expression of
D11b can neither account for the higher migra-
ory properties of CD561hi NK-cells. The mean-
ng of the finding that CD11c is preferentially
xpressed on CD561hi NK-cells is not known.
owever, in a similar way to that occurring for
D11b (31, 32), both C3bi (33, 34), fibrinogen
35) and CD54 (36) have been proposed as li-
ands for CD11c and this molecule has been
laimed to be involved in adhesion to the endo-
helium and to the extracellular matrix (36), as
738ell as to play a role in conjugate formation
etween NK-cells and target cells (37). The sig-
ificance of the exclusive expression of
D57—an oligosaccharide with sulfated glucoro-
ic acid residues that is expressed on T-cells
uring advanced phases of immune responses and
hat presumably also mediates cell adhesion
38)—on CD561lo NK-cells is neither clear.
Besides determining adhesion properties and
igratory capabilities, adhesion molecules may
lso be crucial for conjugate formation between
K-cells and target cells, a process that depends
n the homophilic binding mediated by CD56
39, 40) and on other pairs of receptors such as
D11a/CD54 (41, 42), CD2/CD58 (43, 44), and
D8/MHC-class I antigens (45, 46). Accordingly,
he higher expression of CD56 and CD2 found on
D561hi NK-cells may favor a closer interaction
between these NK-cells and their targets.
Cytotoxicity depends on a delicate balance
between different groups of receptors that either
activate or inhibit the NK-cell killer functions
(47–49) connecting to adapter molecules and
turning on/off different signal-transducing path-
ways (50–53).
CD16—the a-chain of the low-affinity recep-
tor for the Fc portion of IgG (FcgRIII)—activates
ytotoxicity on NK-cells through its binding to
mmune-complexed IgG and plays a determinant
ole in NK-cell proliferation and both antibody-
ependent and antibody-independent cell cytotox-
city (54–59). Absence or low intensity of expres-
ion of CD16 may explain at least to a certain
xtent why both blood and decidual CD561hi
NK-cells are less efficient in mediating non-
MHC-restricted cytotoxicity than the CD561lo
NK-cells (2, 60, 61). Antibody-independent NK-
cell cytotoxic activity is usually related to signals
mediated by multiple immunoglobulin-like
(CD158, NKB1; NKp44; NKp46) and lectin-like
(CD94, CD161) receptors which may act through
an MHC class I dependent (CD94, CD158, and
NKB1) or independent (CD161) pathway (62–
66). Positive stimulation may be initiated through
the activation forms of some of the MHC-depen-
dent receptors, such as CD158 and CD94, and
other non-MHC restricted triggering molecules,
such as CD161, whereas suppresser signals derive
sp
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ceptors mentioned above. As a consequence of
these regulatory mechanisms, differences on the
expression of killer receptors may determine dif-
ferent MHC-dependent activator/suppressive re-
quirements for CD561lo and CD561hi NK-cell
ubsets. For instance, the fact that CD561hi NK-
cells do not express CD158a and NKB1 whereas
they strongly express CD94, may determine spec-
ificity for non-classical HLA-E molecules,
whereas the opposite pattern of expression of
CD158a and NKB1 with low reactivity for CD94
usually observed on CD561lo NK-cells would
suggest a preferential recognition of classical
MHC class I A, B, and C molecules by this cell
subset (67–69).
Higher levels of other molecules that exhibit
NK-cell costimulatory functions on CD561hi NK-
cells such as CD2 (70–72), CD7 (73, 74), CD38
(75, 76), and CD44 (77, 78), may also be related
to a higher ability of NK561hi NK-cells to re-
spond to different stimuli. By contrast, and in
accordance to previous reports, we were not able
to detect surface expression of neither the CD28
(79) nor the CD40L (CD154) (80) costimulatory
molecules on NK-cells.
Interestingly, CD561hi NK-cells exhibited a
henotype suggestive of cell activation, as re-
ected by a higher fraction of HLA-DR1 and
D251 cells (81, 82). The lower intensity of
xpression of CD45RA and the highest proportion
f CD45RA1/CD45RO1 cells among CD561hi
NK-cells may also be a signal of NK-cell activa-
tion, since previous studies have shown that acti-
vated NK-cells transiently acquire CD45RO, a
phenomena that is accompanied by a decrease on
CD45RA expression (83).
NK-cells proliferate and display enhanced cy-
totoxic activity in response to various cytokines
and growth factors, including IL-2 (84–89). Con-
sequently, differences on the expression of cyto-
kine receptors would probably contribute to the
different ability of these NK-cell subsets to be
activated and to proliferate in response to specific
cytokines. The fact that CD122—IL-2R
b-chain—is constitutively expressed with a
higher intensity on CD561hi NK-cells at the same
ime that a higher fraction of these cells express
739D25—IL-2R a-chain—could probably explain
why CD561hi NK-cells display a preferential re-
ponse to low doses of IL-2 with increased cyto-
ytic activity and proliferation compared to the
D561lo NK-cell subset (90–94).
In summary, our results show that CD561hi
and CD561lo NK-cells display distinct pheno-
ypic characteristics suggesting that the former
ells may correspond to a previously activated
K-cell subset with a different pattern of recog-
ition of MHC molecules and different require-
ents to undergo proliferation and activation of
ts cytotoxic functions at the same time that they
ould explain its higher ability to migrate into
ifferent human tissues.
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